Lilly’s “normal” 483
Executive Summary
Lilly receives FDA 483 report "as part of the normal inspection process" for its dry and injectable facilities in Indianapolis. Company says that the outcome of the inspection is not expected to delay the expected fourth quarter launch of the antidepressant Cymbalta, which is manufactured at the dry facility. Inspection ran from May 5-23; the 483 was issued on May 29. Lilly has said that it expects FDA will judge its facilities based on the company's GMP progress rather than its absolute compliance (1"The Pink Sheet" April 28, 2003, p. 31)...
You may also be interested in...
Lilly GMPs Will Not Deter Product Rollout, Firm Says
The remaining Lilly products delayed by good manufacturing practices compliance problems could be approved by FDA before the company has fully implemented its GMP improvement program
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.